ERLOTINIB HYDROCHLORIDE (erlotinib) by Fosun Pharma is protein kinase inhibitors [moa]. Approved for exon 21 (l858r) substitution mutations, maintenance, second and 6 more indications. First approved in 2019.
Drug data last refreshed 18h ago
Protein Kinase Inhibitors
Kinase Inhibitor
Worked on ERLOTINIB HYDROCHLORIDE at Fosun Pharma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
To Evaluate OBI-833/OBI-821 in Combination With First-Line Erlotinib in Patients With EGFR-Mutated, Globo H-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Phase III Study of Nazartinib (EGF816) Versus Erlotinib/Gefitinib in First-line Locally Advanced / Metastatic NSCLC With EGFR Activating Mutations
Randomized Comparative Study of Erlotinib and Pemetrexed in the Maintenance Treatment of Advanced Lung Cancer Patients.
Cabozantinib and Erlotinib for Patients With EGFR and c-Met Co-expressing Metastatic Pancreatic Adenocarcinoma
Study of Ixazomib and Erlotinib in Solid Tumors